Navigation Links
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Date:8/5/2008

BRANFORD, Conn., Aug. 5 /PRNewswire/ -- Marinus Pharmaceuticals, a developer of specialty therapeutics to treat serious neurological, psychiatric and pain disorders, has appointed John Krayacich as president and chief executive officer. Mr. Krayacich will be responsible for leading the company's drug and business development for ganaxolone, an adult and pediatric epilepsy candidate in Phase II, and chelerythrine, a pre-clinical schizophrenia candidate.

Mr. Krayacich brings more than 20 years of experience in pharmaceutical product development with 13 years focused on neuroscience diseases. Most recently, he was with Novartis Pharmaceuticals Corporation where he served as global program head for the antidepressant agomelatine, and vice president and global head of neuroscience project management.

"We are pleased that John is taking the helm at Marinus, particularly at such a crucial stage of development of the company's lead compound, ganaxolone, a new class of epilepsy treatment," said Stephen Bloch, chair of the board of directors and general partner of Canaan Partners. "Marinus has developed an innovative formulation of ganaxolone which we believe sets a foundation for positive clinical outcomes and makes Marinus an exciting investment opportunity."

Prior to Novartis, Mr. Krayacich was vice president of worldwide neurology marketing with Pfizer Pharmaceuticals Group, and Parke-Davis Global Marketing Planning (Atherosclerosis). He was actively involved in the development, strategic marketing planning and/or launch of more than seven neuroscience and cardiovascular compounds including Lipitor(R), Neurontin(R), Lyrica(R), Rebif(R) and the Exelon(R) patch. He has led teams involved in the development and marketing of products for epilepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain, depression, anxiety, Multiple Sclerosis and bipolar disorder.

"I am thrilled to join the Marinus team and to shepherd the company's promising compounds through clinical development and closer to commercialization," said Mr. Krayacich. "I have committed my career to the development of novel therapies that address unmet patient needs and I'm excited about the innovative candidates in the Marinus pipeline."

About Marinus Pharmaceuticals

Marinus Pharmaceuticals is a privately held specialty pharmaceutical company that is dedicated to the identification, development, and commercialization of novel drugs to treat serious neurological, psychiatric and pain disorders. Its lead compound, ganaxolone, is a synthetic analog of the neurosteroid allopregnanolone (3a,5a-P), a metabolite of progesterone. It is currently being investigated in a Phase IIb clinical trial as a potential treatment of epilepsy in children (infantile spasms) and complex partial seizures in adults. Chelerythrine is currently in pre-clinical development for the treatment of bipolar disorder and the cognitive deficits of schizophrenia. Marinus' investors include Domain Associates, Canaan Partners, Sofinnova Ventures and Foundation Medical Partners. For additional information, please visit http://www.marinuspharma.com.

About Domain Associates

Domain Associates, LLC is a venture capital firm focused on health care product opportunities including biopharmaceuticals, medical devices and related businesses. Over its 23 year history, Domain has been involved in the creation of over 200 companies. Its latest venture capital fund is Domain Partners VII, L.P., which is capitalized at $700 million. Domain is located in Princeton, NJ and in San Diego, CA. For more information, please visit http://www.domainvc.com.

About Canaan Partners Healthcare

Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies. For 20 years, the partners have taken an active and committed role in the companies in which they invest, and have completed more than 69 mergers and acquisitions and 52 IPOs. With $3 billion under management and a worldwide footprint, the firm's healthcare team is committed to catalyzing the development of biopharmaceutical, medical device, diagnostic and therapeutics companies that are revolutionizing the practice of medicine. Among recent successes are Cerexa Inc., one of the largest biotech acquisitions of 2007; Advanced BioHealing, a leader in regenerative medicine; and Dexcom Inc., the largest diagnostic IPO of 2005. Other Canaan healthcare investments include Amicus Therapeutics, Chimerix, Inc., ReVision Optics, Inc., and Transoma Medical, Inc. Canaan has offices in California, Connecticut, India and Israel. For more information, visit http://www.canaan.com.

About Sofinnova Ventures

Sofinnova Ventures is a diversified venture capital firm focused on early- stage biopharmaceutical and technology investing. Sofinnova's mission is to provide entrepreneurs with the resources, experience and networks necessary to turn their ideas into thriving businesses. Our life sciences team consists of a seasoned team of five investors and senior executives with deep technical, strategic, and operational experience. Founded in 1974, Sofinnova currently manages over $1 billion and is investing out of its $375M seventh fund. Sofinnova has offices in San Francisco and San Diego. For more information, visit http://www.sofinnova.com.

About Foundation Medical Partners

Foundation Medical Partners is a venture capital investment firm affiliated with The Cleveland Clinic Foundation. The firm is focused solely on health care with a special interest in medical devices, biopharmaceutical platforms and products, and other opportunities in health care including diagnostics, health care services, and health care information systems. Foundation is based in Rowayton, Connecticut.


'/>"/>
SOURCE Marinus Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
2. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
3. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
4. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
5. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
6. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
7. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
10. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
11. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Franz Inc. , an early innovator ... announced the availability of AllegroGraph 6, the leading Semantic Graph Database with certification ... Program (CCPT). AllegroGraph is the first Semantic Graph Database to be certified ...
(Date:2/8/2016)... England , February 8, 2016 ... Ltd ("Atlas Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) ... to CE Mark its Chlamydia trachomatis (CT) test to be ... of the IVD Directive (98/79/EC), the CT test is now ... --> --> The launch of the io® ...
(Date:2/5/2016)... Feb. 5, 2016  In the pharmaceutical industry the ... host of launch activities including the identification and engagement ... activity is especially high in the oncology therapeutic area ... Practices and the Role of Medical Affairs in Oncology ... on oncology therapies find better ways to utilize medical ...
(Date:2/4/2016)... ... February 04, 2016 , ... Morf ... today announced an interactive FDA compliance training course, Writing Effective ... Professional Society) accredited interactive course on Morf Playbook—now conveniently available on smartphones and ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... January 13, 2016 ... addition of the  "India Biometrics Authentication ... Forecast (2015-2020)"  report to their ... has announced the addition of the  ... - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):